[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] VADDEPALLY R K,KHAREL P,PANDEY R,et al.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence[J].Cancers (Basel),2020,12(3):738.
[3] RAMOS-CASALS M,BRAHMER J R,CALLAHAN M K,et al.Immune-related adverse events of checkpoint inhibitors[J].Nat Rev Dis Primers,2020,6(1):38.
[4] SURESH K,NAIDOO J,LIN C T,et al.Immune checkpoint immunotherapy for non-small cell lung cancer:benefits and pulmonary toxicities[J].Chest,2018,154(6):1416-1423.
[5] SU Q,ZHU E C,WU J B,et al.Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors:a systematic review and meta-analysis[J].Front Immunol,2019,10:108.
[6] EL OSTA B,HU F,SADEK R,et al.Not all immune-checkpoint inhibitors are created equal:meta-analysis and systematic review of immune-related adverse events in cancer trials[J].Crit Rev Oncol Hematol,2017,119:1-12.
[7] DENG H,DENG J,LIN X,et al.A risk-scoring model for severe checkpoint inhibitor-related pneumonitis:a case-control study[J].Clin Drug Investig,2023,43(5):347-357.
[8] ATCHLEY W T,ALVAREZ C,SAXENA-BEEM S,et al.Immune checkpoint inhibitor-related pneumonitis in lung cancer:real-world incidence,risk factors,and management practices across six health care centers in North Carolina[J].Chest,2021,160(2):731-742.
[9] PAVAN A,CALVETTI L,DAL MASO A,et al.Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors[J].Oncologist,2019,24(8):1128-1136.
[10] SHAVERDIAN N,LISBERG A E,BORNAZYAN K,et al.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer:a secondary analysis of the KEYNOTE-001 phase 1 trial[J].Lancet Oncol,2017,18(7):895-903.
[11] LIN X,DENG H,YANG Y,et al.Peripheral blood biomarkers for early diagnosis,severity,and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer[J].Front Oncol,2021,11:698832.
[12] MüLLER K M.Histological classification and histogenesis of lung cancer[J].Eur J Respir Dis,1984,65(1):4-19.
[13] 中华医学会呼吸病学分会肺癌学组.免疫检查点抑制剂相关肺炎诊治专家共识[J].中华结核和呼吸杂志,2019,42(11):820-825.
[14] 田雨,陆元花,赵沛妍,等.肺癌免疫治疗相关肺炎生物标志物的研究进展[J].现代医学,2024,52(3):492-498.
[15] NISHINO M,RAMAIYA N H,AWAD M M,et al.PD-1 inhibitor-related pneumonitis in advanced cancer patients:radiographic patterns and clinical course[J].Clin Cancer Res,2016,22(24):6051-6060.
[16] NAIDOO J,WANG X,WOO K M,et al.Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J].J Clin Oncol,2017,35(7):709-717.
[17] WANG H,ZHAO Y,ZHANG X,et al.Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis:a single-institution retrospective study[J].Cancer Med,2021,10(1):188-198.
[18] 王汉萍,郭潇潇,周佳鑫,等.免疫检查点抑制剂相关肺炎的临床诊治建议[J].中国肺癌杂志,2019,22(10):621-626.
[19] DE VELASCO G,JE Y,BOSSō D,et al.Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients[J].Cancer Immunol Res,2017,5(4):312-318.
[20] CHAO Y,ZHOU J,HSU S,et al.Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer[J].Transl Lung Cancer Res,2022,11(2):295-306.
[21] BENJAMIN J T,PLOSA E J,SUCRE J M,et al.Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD[J].J Clin Invest,2021,131(1):e139481.
[22] BRIGHTLING C,GREENING N.Airway inflammation in COPD:progress to precision medicine[J].Eur Respir J,2019,54(2):1900651.
[23] CARAMORI G,RUGGERI P,MUMBY S,et al.Molecular links between COPD and lung cancer:new targets for drug discovery?[J].Expert Opin Ther Targets,2019,23(6):539-553.
[24] BAI R,CHEN N,CHEN X,et al.Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events[J].Cancer Biol Med,2021,18(4):1118-1133.
[25] GRIVENNIKOV S I,GRETEN F R,KARIN M.Immunity,inflammation,and cancer[J].Cell,2010,140(6):883-899.
[26] WU Y,LI D,WU M,et al.Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer[J].Front Oncol,2022,12:1004663.
[27] MA Y,MA X,WANG J,et al.Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors:a retrospective analysis[J].World J Surg Oncol,2022,20(1):242.
[28] CALIMAN E,FANCELLI S,OTTANELLI C,et al.Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy[J].Cancer Treat Res Commun,2022,32:100603.
[29] SIMON S C S,UTIKAL J,UMANSKY V.Opposing roles of eosinophils in cancer[J].Cancer Immunol Immunother,2019,68(5):823-833.
[30] CHU X,ZHAO J,ZHOU J,et al.Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors[J].Lung Cancer,2020,150:76-82. |